---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000006"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:24:59.446462+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zentalis restructures with 40% workforce cut, focuses WEE1 inhibitor, cash to late 2027

## Summary
- Approves workforce reduction of approx. 40%; substantially complete by Q2 2025.
- Expects $7.0-8.0M in one-time termination costs in Q1 2025.
- Believes cash runway extended into late 2027, beyond potential azenosertib data readout.
- Registration-enabling DENALI Part 2 data readout anticipated by end of 2026.
- Corporate event on Jan 29, 2025, to present azenosertib clinical data and regulatory update.

## SEC filing metadata
- accession: 0001725160-25-000006
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/0001725160-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/zntl-20250122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000006
- JSON: https://secwatch.observer/filing/0001725160-25-000006.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000006.txt

## Key facts
- Restructurings & Charges
  Zentalis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $7.0–8.0 million affecting the Company (approximately 40%).
  - Type: restructuring
  - Charge: approximately $7.0–8.0 million
  - Affected area: the Company
  - Headcount: approximately 40%
  source text: On January 22, 2025, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) approved a strategic restructuring of the Company to support execution of late-stage development for the Company’s WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a potentially registration-enabling azenosertib data readout from the Company’s DENALI Part 2 study, anticipated by the end of 2026. In connection with this strategic restructuring, the Company expects to reduce its workforce by approximately 40%. The Company expects to incur one-time costs of approximately $7.0–8.0 million in the first quarter of 2025 in connection with the workforce reduction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000006/0001725160-25-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.